BASINGSTOKE, England, September 13 /PRNewswire-FirstCall/ -- In order to meet its obligations under the Listing Rules of the Financial Services Authority, Shire plc ("Shire") (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) is publishing today its interim results for the six months ended 30 June 2007 in accordance with International Financial Reporting Standards (IFRS).
It should be noted that on 26 July 2007, Shire announced its results in respect of the same period in accordance with US GAAP.
Notes to Editors
Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
For further information on Shire, please visit the Company's website: http://www.shire.com.
Should any shareholder wish to receive a hard copy of the Interim Report, please email Investor Relations on email@example.com.
THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a
number of risks and uncertainties and are subject to change at any time. In
the event such risks or uncertainties ma
|SOURCE Shire plc|
Copyright©2007 PR Newswire.
All rights reserved